159 related articles for article (PubMed ID: 25764575)
1. Promising results Halt phase III studies of idelalisib.
Inman S
Am J Manag Care; 2014 Feb; 20(2 Spec No.):E9. PubMed ID: 25764575
[No Abstract] [Full Text] [Related]
2. Idelalisib for chronic lymphocytic leukemia.
Brown JR
Clin Adv Hematol Oncol; 2014 Dec; 12(12):846-8. PubMed ID: 25674842
[No Abstract] [Full Text] [Related]
3. Idelalisib: targeting PI3Kδ in B-cell malignancies.
Gilbert JA
Lancet Oncol; 2014 Mar; 15(3):e108. PubMed ID: 24809089
[No Abstract] [Full Text] [Related]
4. Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
Barrientos JC
Future Oncol; 2016 Sep; 12(18):2077-94. PubMed ID: 27324214
[TBL] [Abstract][Full Text] [Related]
5. Idelalisib, ibrutinib show benefits in CLL.
Cancer Discov; 2014 Apr; 4(4):382. PubMed ID: 24706642
[No Abstract] [Full Text] [Related]
6. Idelalisib approved for three blood cancers.
Traynor K
Am J Health Syst Pharm; 2014 Sep; 71(17):1430. PubMed ID: 25147161
[No Abstract] [Full Text] [Related]
7. Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib.
Brown JR; Zelenetz A; Furman R; Lamanna N; Mato A; Montillo M; O'Brien S; Dubowy R; Gu L; Munugalavadla V; Robak T; Hillmen P
Leukemia; 2020 Dec; 34(12):3404-3407. PubMed ID: 32655145
[No Abstract] [Full Text] [Related]
8. Idelalisib rapidly improves platelet function tests in patients with chronic lymphocytic leukaemia.
Reda G; Cassin R; Artoni A; Fattizzo B; Lecchi A; La Marca S; Bucciarelli P; Levati GV; Peyvandi F; Cortelezzi A
Br J Haematol; 2018 Dec; 183(5):825-828. PubMed ID: 29315493
[No Abstract] [Full Text] [Related]
9. Idelalisib: a review of its use in chronic lymphocytic leukaemia and indolent non-Hodgkin's lymphoma.
Keating GM
Target Oncol; 2015 Mar; 10(1):141-51. PubMed ID: 25637459
[TBL] [Abstract][Full Text] [Related]
10. Sequential disseminated aspergillosis and pulmonary tuberculosis in a patient treated by idelalisib for chronic lymphocytic leukemia.
Lafon-Desmurs B; Monsel G; Leblond V; Papo M; Caumes E; Fekkar A; Jaureguiberry S
Med Mal Infect; 2017 Jun; 47(4):293-296. PubMed ID: 27818019
[No Abstract] [Full Text] [Related]
11. Idelalisib--a PI3Kδ inhibitor for B-cell cancers.
Fruman DA; Cantley LC
N Engl J Med; 2014 Mar; 370(11):1061-2. PubMed ID: 24620870
[No Abstract] [Full Text] [Related]
12. [Polymicrobial lung infection associated with idelalisib administration].
Rodríguez-Ferreras A; Velasco-Roces L; Lázaro-López E; Zapico-García I
Farm Hosp; 2018 Jan; 42(1):25-26. PubMed ID: 29306311
[No Abstract] [Full Text] [Related]
13. Idelalisib plus rituximab is effective in systemic AL amyloidosis secondary to chronic lymphocytic leukaemia.
Visentin A; Briani C; Imbergamo S; Frezzato F; Angelini A; Fedrigo M; Cacciavillani M; Altinier S; Piazza F; Semenzato G; Adami F; Trentin L
Hematol Oncol; 2018 Feb; 36(1):366-369. PubMed ID: 28971495
[TBL] [Abstract][Full Text] [Related]
14. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
Yang Q; Modi P; Newcomb T; Quéva C; Gandhi V
Clin Cancer Res; 2015 Apr; 21(7):1537-42. PubMed ID: 25670221
[TBL] [Abstract][Full Text] [Related]
15. Idelalisib for the treatment of non-Hodgkin lymphoma.
Graf SA; Gopal AK
Expert Opin Pharmacother; 2016; 17(2):265-74. PubMed ID: 26818003
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of idelalisib for the treatment of indolent B-cell malignancies.
Smolewski P; Rydygier D
Expert Opin Pharmacother; 2020 Oct; 21(15):1915-1926. PubMed ID: 32686971
[TBL] [Abstract][Full Text] [Related]
17. Kinase inhibitors overachieve in CLL.
Garber K
Nat Rev Drug Discov; 2014 Mar; 13(3):162-4. PubMed ID: 24549135
[No Abstract] [Full Text] [Related]
18. The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia.
Brown JR
Semin Oncol; 2016 Apr; 43(2):260-4. PubMed ID: 27040704
[TBL] [Abstract][Full Text] [Related]
19. Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial.
Ghia P; Coutre SE; Cheson BD; Barrientos JC; Hillmen P; Pettitt AR; Zelenetz AD; Shreay S; Hallek M; Furman RR
Haematologica; 2020 Oct; 105(10):e519. PubMed ID: 33054096
[No Abstract] [Full Text] [Related]
20. Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials.
Gordon MJ; Huang J; Chan RJ; Bhargava P; Danilov AV
Br J Haematol; 2021 Feb; 192(4):720-728. PubMed ID: 32599655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]